Table 2 Relative Metabolic Rate in Prefrontal Cortex in Normal Subjects and Impulsive/Aggressive Patients: Fenfluramine Effect Difference

From: d,l-fenfluramine Response in Impulsive Personality Disorder Assessed with [18F]fluorodeoxyglucose Positron Emission Tomography

  Patients Normal Subjects Normal Patient
  Right Left Right Left Right Left
Regions Placebo Fen Placebo Fen Placebo Fen Placebo Fen Fen Placebo
Superior dorsolateral           
1 0.90 0.94 0.98 0.97 0.83 0.90 0.94 1.00 0.03 0.07
2 1.00 1.03 1.00 1.09 0.91 1.01 0.97 1.09 0.07 0.03
3a 1.08 1.05 1.08 1.16 0.96 1.08 1.02 1.10 0.15 0.00
4a 1.14 1.11 1.18 1.24 1.09 1.19 1.10 1.18 0.13 0.02
Mid-dorsolateral           
5a 1.17 1.22 1.20 1.28 1.14 1.28 1.21 1.24 0.09 −0.05
6a 1.23 1.28 1.22 1.32 1.19 1.32 1.27 1.28 0.08 −0.09
7a 1.26 1.29 1.25 1.38 1.26 1.33 1.25 1.28 0.04 −0.10
8a 1.30 1.28 1.26 1.37 1.26 1.31 1.26 1.30 0.07 −0.07
Orbital lateral           
9a 1.26 1.21 1.25 1.32 1.19 1.21 1.21 1.27 0.07 0.04
10 1.17 1.12 1.23 1.23 1.10 1.12 1.12 1.17 0.07 0.05
11b 1.08 1.07 1.11 1.05 0.98 1.01 0.99 1.09 0.04 0.16
12a 1.00 1.03 1.02 0.99 0.94 0.96 0.96 1.04 −0.01 0.05
Orbital surface           
13a,c 0.96 1.00 0.99 0.98 0.94 0.99 0.88 0.98 0.00 0.11
14a 0.89 0.94 0.92 0.92 0.91 0.90 0.86 0.91 −0.06 0.06
15a,c 0.94 0.98 0.88 0.98 0.94 0.98 0.93 0.94 0.00 −0.08
16 0.97 0.96 0.97 0.99 0.98 1.01 0.95 1.00 0.04 0.03
  1. Omnibus test across groups; Drug condition × hemisphere × region × group interaction: F = 5.16, df = 12.4, 11, p < .0001. Drug condition × hemisphere × group interaction (F = 7.73, df = 1,9, p < .02). Data are not shown for dug condition × hemisphere × region × group × slice (F = 1.49, df = 49.8, 448, p < .01).
  2. Omnibus test in normal subjects only; Drug condition × hemisphere × regions interaction, F = 2.50, p = .056. Omnibus test in patients only: drug condition × hemisphere: F = 14.95, df = 1,9, p = .0038; drug condition × hemisphere × region interaction: F = 4.54, df = 12.4, 111.8, p < .0001.
  3. Followup ANOVA on each cortical segment from superior dorsal (1) to orbital medial (16).
  4. a Drug condition × group × hemisphere condition interaction significant for individual sector, p < .05.
  5. b Drug condition × group interaction significant.
  6. c Drug condition × hemisphere × group × anteroposterior slice significant; data not shown.